In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Rosalind Advisors, Inc. reported 29 stock positions worth $266.2 million . Its top holding was Delcath Systems (DCTH) at 15.6% of the portfolio, followed by Fennec Pharmaceuticals (FENC, 12.9% ) and Xeris Biopharma (XERS, 8.7% ). Compared with Q1 2026, it opened 3 new positions, sold out of 6, added to 7 and reduced 11. The biggest buy was Fennec Pharmaceuticals (FENC, shares +10% ) and the biggest sale an exit from CG Oncology (CGON).
Location TORONTO, A6
CIK 0001622627
Portfolio Value $266.2M (Q2 2026) Holdings 29 stocks · $266.2M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2026 DCTH Delcath Systems Inc. 3,300,389 $41.6M No change FENC Fennec Pharmaceuticals Inc. 3,188,001 $34.3M Add +9.6% XERS Xeris Biopharma Holdings Inc. 2,908,981 $23.0M Reduce -10.0% SVRA Savara Inc. 3,178,121 $19.6M Reduce -0.8% VSTM Verastem Inc. 3,986,509 $15.2M Add +86.4% XFOR X4 Pharmaceuticals Inc. 3,214,766 $15.0M No change EYPT Eyepoint Inc. 988,230 $14.1M Reduce -4.7% HELP Cybin Inc. 1,956,814 $12.9M Add +27.7% VOR Vor Biopharma Inc. 648,600 $11.9M Reduce -7.3% PCVX Vaxcyte Inc. 200,000 $11.6M Reduce -31.0% MDWD Mediwound Ltd. 749,054 $11.0M No change CLDX Celldex Therapeutics Inc. 200,000 $7.4M Reduce -39.4% BCRX Biocryst Pharmaceuticals Inc. 721,504 $7.2M Reduce -21.8% PROF Profound Medical Corp. 828,118 $5.5M No change TLPH Talphera Inc. 5,169,501 $5.3M Add +54.1% AVIR Atea Pharmaceuticals Inc. 1,070,550 $5.0M Reduce -8.6% MYO Myomo Inc. 3,637,886 $3.8M Reduce -5.4% OVID Ovid Therapeutics Inc. 1,107,994 $3.0M No change NRXS Neuraxis Inc. 508,055 $3.0M Add +77.6% ABVX Abivax SA-ADR 20,869 $2.8M New NSPR Inspiremd Inc. 3,905,743 $2.7M No change RGNT Regentis Biomaterials Ltd. 701,685 $2.5M Add +179.0% PYPD Polypid Ltd. 389,455 $2.0M Reduce -34.9% BFRI Biofrontera Inc. 1,275,609 $1.2M Add +9.6% KURA Kura Oncology Inc. 100,000 $1.1M No change SPRB Spruce Biosciences Inc. 20,000 $1.1M New AQST Aquestive Therapeutics Inc. 250,000 $1.0M No change OKUR Onkure Therapeutics Inc. Class A 150,000 $684K Reduce -66.2% PEPG Pepgen Inc. 350,000 $630K New
Options reported separately and not counted above: SELLAS LIFE SCIENCES GROUP I puts ($2.3M), CG ONCOLOGY INC calls ($375K), EYEPOINT PHARMACEUTICALS INC calls ($131K), ISHARES TR puts ($110K), SPDR SERIES TRUST puts ($35K), TENAX THERAPEUTICS INC puts ($14K).
Portfolio Sells Q1 2026 → Q2 2026 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2026 % Of Portfolio Change To Portfolio ▲ CGON CG Oncology Inc. Sold out 0.00% −2.77 PCVX Vaxcyte Inc. Reduce -31.0% 4.37% −2.54 VRDN Viridian Therapeutics Inc. Sold out 0.00% −2.01 CLDX Celldex Therapeutics Inc. Reduce -39.4% 2.80% −1.49 DFTX Definium Therapeutics Inc. Sold out 0.00% −0.97 BCRX Biocryst Pharmaceuticals Inc. Reduce -21.8% 2.71% −0.89 LPCN Lipocine Inc. Sold out 0.00% −0.73 AVIR Atea Pharmaceuticals Inc. Reduce -8.6% 1.87% −0.71 VOR Vor Biopharma Inc. Reduce -7.3% 4.49% −0.63 OKUR Onkure Therapeutics Inc. Class A Reduce -66.2% 0.26% −0.50 AVTX Avalo Therapeutics Inc. Sold out 0.00% −0.46 ANNX Annexon Inc. Sold out 0.00% −0.45 PYPD Polypid Ltd. Reduce -34.9% 0.74% −0.33 EYPT Eyepoint Inc. Reduce -4.7% 5.31% −0.17 SVRA Savara Inc. Reduce -0.8% 7.35% +0.19 MYO Myomo Inc. Reduce -5.4% 1.42% +0.36 XERS Xeris Biopharma Holdings Inc. Reduce -10.0% 8.65% +0.97
Portfolio Buys Q1 2026 → Q2 2026 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2026 % Of Portfolio Change To Portfolio ▼ FENC Fennec Pharmaceuticals Inc. Add +9.6% 12.87% +5.54 HELP Cybin Inc. Add +27.7% 4.86% +1.85 VSTM Verastem Inc. Add +86.4% 5.72% +1.08 ABVX Abivax SA-ADR New 1.04% +1.04 TLPH Talphera Inc. Add +54.1% 2.00% +0.97 RGNT Regentis Biomaterials Ltd. Add +179.0% 0.93% +0.62 NRXS Neuraxis Inc. Add +77.6% 1.12% +0.42 SPRB Spruce Biosciences Inc. New 0.41% +0.41 PEPG Pepgen Inc. New 0.24% +0.24 BFRI Biofrontera Inc. Add +9.6% 0.45% +0.07
Options Activity Q1 2026 → Q2 2026 Security Type Change vs Q1 2026 Underlying Shares Value ▼ REPLIMUNE GROUP INC call Sold out 1,275,600 $2.7Mbefore exit SELLAS LIFE SCIENCES GROUP I put New 568,700 $2.3M INVESCO QQQ TR put Sold out 250,000 $1.1Mbefore exit STATE STR SPDR S&P 500 ETF T put Sold out 125,000 $959Kbefore exit CG ONCOLOGY INC call New 31,000 $375K EYEPOINT PHARMACEUTICALS INC call New 50,300 $131K ISHARES TR put New 500,000 $110K VIRIDIAN THERAPEUTICS INC put Sold out 263,600 $53Kbefore exit SPDR SERIES TRUST put New 140,600 $35K TENAX THERAPEUTICS INC put New 6,200 $14K ARRIVENT BIOPHARMA INC call Sold out 108,900 $0before exit UNIQURE NV call Sold out 295,800 $0before exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 29 $266.2M DCTH, FENC, XERS, SVRA, VSTM Q1 2026 32 $244.1M DCTH, XERS, FENC, SVRA, PCVX Q4 2025 29 $274.5M DCTH, SVRA, FENC, XERS, VRDN Q3 2025 29 $283.0M DCTH, CYTK, FENC, VSTM, RZLT Q2 2025 29 $206.6M DCTH, FENC, CYTK, OCUL, IDYA Q1 2025 31 $205.2M DCTH, VSTM, XERS, MYO, IDYA Q4 2024 Amended 28 $185.7M DCTH, MYO, MDWD, CMRX, XERS Q3 2024 29 $150.7M DCTH, MYO, CRMD, ABEO, MDWD Q2 2024 35 $126.5M DCTH, MYO, MDWD, OPTINOSE INC, ABEO Q1 2024 31 $106.9M MYO, LYRA, MDWD, OPTINOSE INC, XERS